



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)
(AIM: HCM)**

Director’s Shareholding

London: Thursday, 13 September 2012: Chi-Med received notification on 13 September 2012 that Mr Michael Howell, Independent Non-executive Director of Chi-Med, purchased 31,800 ordinary shares of US\$1.00 each in Chi-Med (the “Shares”) at a price of GBP4.35 each on 11 September 2012.

Following this purchase, Mr Howell is beneficially interested in 153,600 Shares, representing approximately 0.30% of the current issued share capital of Chi-Med.

Ends

Enquiries

Chi-Med Christian Hogg, CEO	Telephone: +852 2121 8200
Citigate Dewe Rogerson Anthony Carlisle David Dible	Telephone: +44 20 7638 9571 Mobile: +44 7973 611 888 Mobile: +44 7967 566 919
Panmure Gordon (UK) Limited Richard Gray Andrew Potts Grishma Patel	Telephone: +44 20 76148383

About Chi-Med

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.